These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36523562)

  • 1. Study on potential markers for diagnosis of renal cell carcinoma by serum untargeted metabolomics based on UPLC-MS/MS.
    Wang J; Yang WY; Li XH; Xu B; Yang YW; Zhang B; Dai CM; Feng JF
    Front Physiol; 2022; 13():996248. PubMed ID: 36523562
    [No Abstract]   [Full Text] [Related]  

  • 2. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
    Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
    BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
    Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
    Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC.
    Liu X; Zhang M; Liu X; Sun H; Guo Z; Tang X; Wang Z; Li J; Li H; Sun W; Zhang Y
    Front Oncol; 2019; 9():663. PubMed ID: 31380290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Untargeted Metabolomics Reveal Potential Biomarkers of Progression of Diabetic Retinopathy in Asians.
    Wang Z; Tang J; Jin E; Zhong Y; Zhang L; Han X; Liu J; Cheng Y; Hou J; Shi X; Qi H; Qian T; Yuan L; Hou X; Yin H; Liang J; Zhao M; Huang L; Qu J
    Front Mol Biosci; 2022; 9():871291. PubMed ID: 35755823
    [No Abstract]   [Full Text] [Related]  

  • 6. [Lipid metabolomic analysis in exosomes of osteonecrosis of the femoral head based on ultra performance liquid chromatography-tandem mass spectrometry].
    Guo M; Zhang J
    Se Pu; 2022 Feb; 40(2):123-129. PubMed ID: 35080158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum amino acid metabolic profiles of ankylosing spondylitis by targeted metabolomics analysis.
    Zhou Y; Zhang X; Chen R; Han S; Liu Y; Liu X; Gao M; Yang C; Lu D; Sun B; Chen H
    Clin Rheumatol; 2020 Aug; 39(8):2325-2336. PubMed ID: 32130577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone.
    Xu B; Chen Y; Chen X; Gan L; Zhang Y; Feng J; Yu L
    Front Oncol; 2021; 11():730638. PubMed ID: 34722271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
    Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
    Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum metabolomic analyses reveal the potential metabolic biomarkers for prediction of amatoxin poisoning.
    Liu Y; Li S; Feng Y; Zhang Y; Ouyang J; Li S; Wang J; Tan L; Zou L
    Toxicon; 2023 Jul; 230():107153. PubMed ID: 37178797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study.
    Oto J; Fernández-Pardo Á; Roca M; Plana E; Solmoirago MJ; Sánchez-González JV; Vera-Donoso CD; Martínez-Sarmiento M; España F; Navarro S; Medina P
    J Proteomics; 2020 Apr; 218():103723. PubMed ID: 32126320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery.
    Lin L; Huang Z; Gao Y; Yan X; Xing J; Hang W
    J Proteome Res; 2011 Mar; 10(3):1396-405. PubMed ID: 21186845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum metabolomics of end-stage renal disease patients with depression: potential biomarkers for diagnosis.
    Yuan D; Kuan T; Ling H; Wang H; Feng L; Zhao Q; Li J; Ran J
    Ren Fail; 2021 Dec; 43(1):1479-1491. PubMed ID: 34723750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Untargeted Metabolomics Analysis of Esophageal Squamous Cell Carcinoma Discovers Dysregulated Metabolic Pathways and Potential Diagnostic Biomarkers.
    Zhu ZJ; Qi Z; Zhang J; Xue WH; Li LF; Shen ZB; Li ZY; Yuan YL; Wang WB; Zhao J
    J Cancer; 2020; 11(13):3944-3954. PubMed ID: 32328198
    [No Abstract]   [Full Text] [Related]  

  • 15. [Plasma metabolomics in a deep vein thrombosis rat model based on ultra-high performance liquid chromatography-electrostatic field orbitrap high resolution mass spectrometry].
    Gu Y; Zang P; Li J; Yan Y; Wang J
    Se Pu; 2022 Aug; 40(8):736-745. PubMed ID: 35903841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.
    Wang R; Kang H; Zhang X; Nie Q; Wang H; Wang C; Zhou S
    BMC Cancer; 2022 Feb; 22(1):214. PubMed ID: 35220945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum metabolic profiling analysis of gout patients based on UPLC-Q-TOF/MS.
    Zhong Z; Huang Y; Huang Q; Zheng S; Huang Z; Deng W; Li T
    Clin Chim Acta; 2021 Apr; 515():52-60. PubMed ID: 33388309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Throughput Untargeted Serum Metabolomics Analysis of Hyperuricemia Patients by UPLC-Q-TOF/MS.
    Qin N; Jiang Y; Shi W; Wang L; Kong L; Wang C; Guo Y; Zhang J; Ma Q
    Evid Based Complement Alternat Med; 2021; 2021():5524772. PubMed ID: 34234835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LC-MS-Based Plasma Metabolomics and Lipidomics Analyses for Differential Diagnosis of Bladder Cancer and Renal Cell Carcinoma.
    Liu X; Zhang M; Cheng X; Liu X; Sun H; Guo Z; Li J; Tang X; Wang Z; Sun W; Zhang Y; Ji Z
    Front Oncol; 2020; 10():717. PubMed ID: 32500026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SELDI-TOF-MS-based serum proteomic screening in combination with CT scan distinguishes renal cell carcinoma from benign renal tumors and healthy persons.
    Xu G; Xiang CQ; Lu Y; Wang WJ; Kang XN; Liao P; Ding Q; Zhang YF
    Technol Cancer Res Treat; 2009 Jun; 8(3):225-30. PubMed ID: 19445540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.